glp-1 employer coverage news october 2025 Medicare Drug ISPOR 2025: Exploring reasons for

In studies of healthy individuals, Bryrup et al

GLP-1 innovation to-date: A duel at the top The GLP-1 market to-date has largely been a two-horse race between Novo Nordisk and Eli Lilly

Ongoing clinical trials are planned, including evaluating tirzepatide as adjunctive therapy in individuals with a BMI over 27 who are already receiving infliximab or adalimumab treatment (NCT06774079)

These medications were originally developed to help manage type 2 diabetes, but they also support weight loss by slowing stomach emptying, stabilizing blood sugar levels, and increasing feelings of fullness and satisfaction, which can reduce appetite

Over time, these tools help you enjoy the thrill while staying anchored to your limitsproof that good design can be both entertaining and protective